A randomised, double-blind, placebo controlled study of AIMSPRO in Mul
A randomised, double-blind, placebo controlled study of AIMSPRO in Multiple Sclerosis
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- AIMSPRO
What it measured
Main measures
Change in average voided volume
Bladder, bowel and sexual function
Who could take part
Progressive MS
Show the full criteria
Inclusion criteria
Inclusion: Patients who meet all of the following criteria will be eligible for study enrolment Exclusion: If any of the following exclusion criteria are met, the patient is ineligible for the study:
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
This is a proof of concept study. We seek to identify a signal that would justify further development of this drug, on the grounds of reasonable probability of true efficacy in the management of patients with multiple sclerosis (MS). To date, Some 400 patients with MS have now taken the medication for periods of up to 5 years. The most commonly reported benefit has been an improvement in bladder function, so it is judged that it would be best to conduct a proof of concept study on the overactive bladder symptoms associated with MS.
Loading reviews and guidelines…
History
Started
Jun 2007